With increasing incidences of cardiovascular and cerebrovascular diseases, this category of drugs have become one of the major areas in the world’s pharmaceutical market. World Health Organisation has listed Osteoarthritis, cancer and cardiovascular diseases as the three main threats to public health.
According to Southern Medicine and Economy Research Institution (南方醫藥經濟研究所), sales of cardiovascular and cerebrovascular drugs accounted for 14.36% of the pharmaceutical market in the PRC.
It is expected our first product in this category - Low-molecular Weight Heparin Sodium Injection (活多史 “Huo Duoshi”) will be launched in June this year. We are confident that this product will be well received by the market and giving us a good starts in entering the cerebro-cardiovascular drug market.
In addition to this prime product, there are three other products that are currently developing by the group: Buflomedil Pyridoxal Phosphate capsules for peripheral vascular diseases, Edaravone for Injection for acute ischemic stroke and Huaqixong Effervescent Tablets for coronary heart diseases.
Low Molecular Weight Heparin Sodium Injection (活多史, “Huo Duoshi”)
In China, it is estimated that more than 2.6 million people are died every year because of thrombotic diseases; as such, the demand for drugs in preventing the formation of thrombosis is huge. Since 2002, 27% of the Thrombosis drug market was attributable to Low Molecular Weight Heparin drugs. It is also currently widely used for anti-coagulation during hemodialysis, as well as anti-thrombosis during vascular and orthopaedic surgeries.
According to SFDA, total sales of Low Molecular Weight Heparin amounted to RMB 210 million in 2004, of which imported drugs are dominating, enjoying more than 80% of market share.
The Low Molecular Weight Heparin produced by the Group is the only pre-filled syringe of its category made in China with a selling price 40% lower than the imported drugs of the same quality.